Abstract 429P
Background
Melanoma care is revolutionized with checkpoint inhibitors (CPI) and targeted therapies; however, access to drugs is challenging in Low-Middle income countries (LMICs).
Methods
Histologically proven melanoma cases registered from 2013–2019 were analysed.
Results
There were 443 patients with median age of 54 years; 60% were males with 41% cutaneous, and 57% mucosal melanomas; most common primary sites were anorectal (41%) and extremities (27%); 11% were BRAF mutated. Among the 258 non-metastatic patients, the median follow up was 30 months (0–83 months). Of these, 114 (44%) had prior surgery and 73 (64%) were already metastatic at presentation to us. Of the remaining 144 (56%), 101 underwent resection, 11 were unresectable, and rest 32 did not take treatment. Median EFS of non-metastatic patients was 17 (95% CI: 11-23) months while median OS was 38 months (95% CI: 30-46); 2-years OS predictions was 66% (95% CI: 59-73). Overall metastatic cohort (n=311) comprised of baseline metastatic (n=185) and non-metastatic patients with (73) or without prior therapy (53) who failed with distant metastasis.Commonest metastatic sites were liver (52%) and non-regional nodes (51%). Median follow up in this cohort was 21 (0–74 months); 138 (44.4%) received chemotherapy(taxane, dacarbazine), Interferons, while 29 (9.3%) patients received CPI. The clinical benefit rate was 31%. In baseline metastatic cohort, the median EFS and OS with BSC alone were 3.8 (95% CI: 2.6-5.0) months and 3.5 (95% CI: 2.45-4.63) vs. 5.55 (95% CI: 3-8) months and 11 (95% CI: 9-13.1) months in any systemic therapy group (HR for OS: 0.34, 95% CI: 0.22-0.52; P<0.001). Grade 3/4 toxicity were observed in 16 % with predominance of thrombocytopenia and anemia (both 4%) in chemotherapy and anemia (10%) for CPI. Any therapy received was significant in both cohort;additionally, site, surgery, were significant in non-metastatic cohort.
Conclusions
This real-world data from India reflects the hard reality of access of expensive, standard of care therapies. Interesting finding that any systemic therapy can lead to meaningful clinical benefits at-least in a select group of patients merits exploration if standard options are not feasible, especially in LMICs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session